Comparison etiketine sahip kayıtlar gösteriliyor. Tüm kayıtları göster
Comparison etiketine sahip kayıtlar gösteriliyor. Tüm kayıtları göster

3 Nisan 2017 Pazartesi

Anti-abortion group in tampon tax row removes death penalty comparison

A charity that has been given £250,000 from the government’s so-called tampon tax fund has scrubbed language describing abortion after rape as a “death penalty” from its website after being challenged on it.


The Life charity has now said it will do a full review of its website to remove offensive language, after the Guardian pointed out that the same article referred to abortion in cases of disability as a “death sentence”.


Life, which campaigns against abortion, was among 70 organisations working with women and girls to receive funding from the £12m tampon tax fund set up by George Osborne.


The £250,000 funding will go into housing and counselling services run by Life for homeless pregnant women in west London, the government announced. But the decision to award Life funding provoked concern among some women’s groups.


On Monday, Life’s education director Anne Scanlan was challenged on the BBC Radio 4’s Today programme about a piece on the charity’s website in which abortion after rape was described as a “death penalty”.


Ann Furedi, of the British Pregnancy Advisory Service, brought up the phrasing and said: “You cannot be saying on one hand that you provide an unbiased, non-judgemental approach to dealing with women when this is the ideological motivation of your organisation.”


Scanlan responded: “I cannot believe we use that terminology at all, we would absolutely never use that kind of language face to face when dealing with women.”


The article was swiftly edited on Monday morning to remove the description. However, the same article still referred to abortion in cases of disability as a “death sentence”.


When the Guardian pointed this out, Scanlan said the language was inappropriate and offensive, and pledged to review all content on the website. “Where inappropriate language was used, we will amend it or remove it,” she said.


“We offer help and support to women. We certainly don’t want anything on the website that’s offensive,” Scanlan said. “We are not going to shy away from it: we are an anti-abortion organisation. But I was genuinely surprised to find out that language was being used on our website.”


Scanlan said she did not know how long the article had been online but believed it was written before she arrived at Life six years ago and had slipped through the net when the website was revamped last year. “Unfortunately a whole swathe of briefing papers have been moved from the old website without being adequately checked,” she said.


She denied that the group’s opposition to abortion made it unsuitable to receive the tampon tax funding. “We never, ever try to push our views onto anybody else,” she said, adding Life provides “non-directive counselling” that avoids recommending any particular course of action. “When it comes to providing support for women, we’re not debating the issue: we are just providing support,” she added.


Furedi told the Guardian she did not believe it was possible to separate Life’s opposition to abortion from the advice it provides to women. “Organisations are led by their values, and that runs through advocacy and campaigning, but it also runs through the way services are delivered,” she said, adding: “What they are saying is abortion has, as far as they are concerned, no place in the management of problem pregnancy.”


The government’s decision to provide funding to an anti-abortion organisation was a “slap in the face” to public opinion, which is increasingly supportive of choice, Furedi said, pointing out that the £250,000 was among the largest grants handed out: “Every woman who’s buying sanitary protection is being caused to effectively make a donation [to Life]”. The charity has a turnover of £3.6m a year.


A spokesperson for the Department for Culture, Media and Sport, which determines how the tampon tax fund is distributed, said the money is being spent to “help improve the lives of disadvantaged women and girls, including those who have been affected by violence,” adding: “Life has been awarded £250,000 to fund a specific project in west London that will help homeless and other at risk women who are pregnant by providing housing, counselling and life skills training.”


The government declined to comment on whether it had any concerns about providing significant funding to an avowedly pro-life organisation.



Anti-abortion group in tampon tax row removes death penalty comparison

30 Mart 2014 Pazar

1st TAVR Comparison Trial Favors Sapien XT Over CoreValve

With two units now approved for transcatheter aortic valve substitute (TAVR), the marketing battle has begun to win the hearts and minds of cardiologists. On Saturday at the ACC, Medtronic acquired bragging rights exhibiting the 1st mortality advantage for its CoreValve gadget. A equivalent improvement did not arise in the Companion trials with the Edwards Sapien gadget, but all the professionals have warned against cross-trial comparisons. Now an actual randomized trial has emerged evaluating the two platforms. The outcomes favor the Sapien XT, but the size and scope of the trial imply that the discussion and debate will definitely carry on.


Selection, presented at the American School of Cardiology meeting in Washington, DC, and published simultaneously in JAMA, was an investigator-initiated trial in which 241 sufferers with significant aortic stenosis had been randomized to the Edwards Sapien XT or the Medtronic CoreValve at 5 centers in Germany. The primary endpoint was gadget accomplishment, defined as implantation of the gadget in the right position with minor or no regurgitation.


Device good results was achieved in 95.9% of patients who obtained the balloon-expandable Sapien XT and in 77.five% of patients who received the self-expandable CoreValve (relative threat, one.24 95% CI, one.twelve-one.37 P&lt0.001). The investigators attributed this variation to a substantial reduction in a lot more-than-mild aortic regurgitation (four.one% vs. 18.three% RR, .23 95% CI, .09-.58 P&lt0 .001) and to a diminished need to have to implant far more than one valve (.eight% vs. 5.eight% P=.03) in the Sapien group.


There was no considerable variation in cardiovascular mortality at thirty days, bleeding and vascular problems, or in a combined safety endpoint. But a new pacemaker was essential less typically in the Sapien group (17.three% vs. 37.six% P=.001). Improvement in signs and symptoms and high quality-of-lifestyle measures were much more widespread in the Sapien group. The investigators speculated that the tighter seal of the balloon-expandable Sapien XT could account for some of the variations that emerged in the trial.


“This is a extremely dynamic discipline,” lead author Abdel-Wahab stated. “We now have new valves coming out that will almost certainly be even far better, but we do not have ample information about them but. These outcomes can help to inform the layout of long term gadgets.”


In an accompanying editorial, E. Murat Tuzcu and Samir Kapadia consider note of the positive aspects witnessed with the Sapien XT in the trial, such as the main endpoint of device success. They caution, nonetheless, that it “should not be interpreted as a surrogate for long-phrase outcomes such as death, stroke, and top quality of lifestyle.”



1st TAVR Comparison Trial Favors Sapien XT Over CoreValve